95629-02-0

Basic information

• Product Name: 3-BROMO-4-OXO-PIPERIDINE-1-CARBOXYLIC ACID ETHYL ESTER
• Synonyms: 3-BROMO-4-OXO-PIPERIDINE-1-CARBOXYLIC ACID ETHYL ESTER;ETHYL 3-BROMO-4-OXO-PIPERIDINE-1-CARBOXYLATE;N-Carboethoxy-3-Bromo-4-Piperidone;1CARBETHOXY-3-BRONO-4-PIPERIDONE;1CARBETHOXY-3-BROMO-4-PIPERIDONE;3-Bromo-4-oxo-piperidine-1-caroboxylic acid ethyl ester;1-Piperidinecarboxylic acid, 3-broMo-4-oxo-, ethyl ester;3-bromo-4-oxo-1-ethoxycarbonyl-piperidine
• CAS NO: 95629-02-0
• Molecular Formula: C₈H₁₂BrNO₃
• Molecular Weight: 250.09
• Mol File: 95629-02-0.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 320.161 °C at 760 mmHg
• Flash Point: 147.428 °C
• Appearance: /
• Density: 1.539g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.529
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 3-BROMO-4-OXO-PIPERIDINE-1-CARBOXYLIC ACID ETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BROMO-4-OXO-PIPERIDINE-1-CARBOXYLIC ACID ETHYL ESTER(95629-02-0)
• EPA Substance Registry System: 3-BROMO-4-OXO-PIPERIDINE-1-CARBOXYLIC ACID ETHYL ESTER(95629-02-0)

Safety Data

• Hazardous Substances Data: 95629-02-0(Hazardous Substances Data)

Usage

General Description

3-Bromo-4-oxo-piperidine-1-carboxylic acid ethyl ester is a chemical compound with the molecular formula C8H11BrNO3. It is an ethyl ester derivative of piperidine-1-carboxylic acid and contains a bromine atom and a carbonyl group on the piperidine ring. 3-BROMO-4-OXO-PIPERIDINE-1-CARBOXYLIC ACID ETHYL ESTER can be used in organic synthesis and pharmaceutical research as a building block for the synthesis of various piperidine derivatives. It is also a potential precursor in the production of pharmaceuticals and agrochemicals. The chemical properties and reactivity of 3-bromo-4-oxo-piperidine-1-carboxylic acid ethyl ester allow for its use in the development of biologically active compounds for a variety of applications.

InChI:InChI=1/C8H12BrNO3/c1-2-13-8(12)10-4-3-7(11)6(9)5-10/h6H,2-5H2,1H3

Upstream product

• 29976-53-2 N-ethoxycarbonyl-4-piperidone 
• 7789-45-9 copper(II)bromide 

Downstream Products

• 623932-10-5 ethyl 3-{[(3-ethoxycarbonyl)-1H-pyrazol-5-yl]oxy}-4-oxopiperidine-1-carboxylate 
• 83898-43-5 ethyl 3-hydroxy-4,4-dimethoxy-1-piperidinecarboxylate 
• 1206612-18-1 2-[4-(4-methoxycarbonyl-phenyl)-tetrahydro-pyran-4-yl]-6,7-dihydro-4H-thiazolo[5,4-c]pyridine-5-carboxylic acid ethyl ester 
• 1206611-98-4 C₂₀H₂₄N₂O₅S 
• 1363281-30-4 5-(cyclopropylacetyl)-4,5,6,7-tetrahydro-2-(phenoxymethyl)-oxazolo[5,4-c]pyridine 
• 1363281-33-7 5-(3,5-difluorobenzoyl)-4,5,6,7-tetrahydro-2-(phenoxymethyl)-oxazolo[5,4-c]pyridine 
• 1363282-10-3 2-(phenoxymethyl)-5-(trifluoroacetyl)-4,5,6,7-tetrahydro[1,3]oxazolo[5,4-c]pyridine 
• 1363286-16-1 2-(1,2-dihydroxy-2-phenylethyl)-6,7-dihydro-oxazolo[5,4-c]pyridine-5(4H)-carboxylic acid ethyl ester 
• 1363286-25-2 ethyl 2-(phenoxymethyl)-6,7-dihydro-4H-oxazolo[5,4-c]pyridine-5-carboxylate 
• 1363286-28-5 2-(phenoxymethyl)-4,5,6,7-tetrahydrooxazolo[5,4-c]pyridine 
• 1363281-27-9 (4-fluorophenyl)-[2-(phenoxymethyl)-6,7-dihydro-4H-oxazolo[5,4-c]pyridin-5-yl]methanone 
• 1363286-13-8 6,7-dihydro-2-[(E)-2-phenylethenyl]-oxazolo[5,4-c]pyridine-5(4H)-carboxylic acid ethyl ester 
• 1190971-76-6 tert-butyl 2-(hydroxymethyl)-6,7-dihydrothiazolo[5,4-c]pyridine-5(4H)-carboxylate 
• 1190970-39-8 2-[[(2S)-1-[(4-methoxy-2,6-dimethyl-phenyl)sulfonyl]-piperidin-2-yl]-methoxy]-1-[2-(piperidin-1-yl-methyl)-4,5,6,7-tetrahydro-thiazolo[5,4-c]pyridin-5-yl]-ethanone 

Relevant articles and documents

Further optimization of the mGlu5 PAM clinical candidate VU0409551/JNJ-46778212: Progress and challenges towards a back-up compound

This Letter describes the progress and challenges in the continued optimization of the mGlu5 positive allosteric modulator (PAM) clinical candidate VU0490551/JNJ-46778212. While many analogs addressed key areas for improvement, no one compound possessed the amalgamation of improvements needed within the (2(phenoxymethyl)-6,7-dihydrooxazolo[5,4-c]pyridine-5(4H)-yl(aryl)methanone scaffold to advance as a back-up clinical candidate. However, many analogs displayed excellent solubility and physiochemical properties, and were active in the amphetamine-induced hyperlocomotion (AHL) model. Moreover, the SAR was robust for this series of PAMs, and both polar and hydrogen-bond donors were found to be tolerated, leading to analogs with overall attractive profiles and good ligand efficiencies. Graphical abstract

SUBSTITUTED SULFONAMIDE DERIVATIVES

The invention relates to substituted sulfonamide derivatives, processes for the preparation thereof, medicaments containing these compounds and the use of substituted sulfonamide derivatives for the preparation of medicaments.

N-acylamino acid amide compounds and intermediates for preparation thereof

The present invention discloses the compound represented by the formula (I): wherein A represents the following formula (a-1) or the following formula (a-2): B represents the following formula (b): (wherein the symbols are each as defined in the specification) or a pharmaceutically acceptable salts thereof, and intermediates for the preparation thereof, which have excellent platelet aggregation inhibitory activity and other properties and useful as prophylactic or therapeutic agents for diseases associated with a fibrinogen receptor, thrombosis, infarction and the like.